SHA: 688837

OrbusNeich Completes Acquisition of Italian Distributor MC Health – 100% Equity Deal Shifts Italy Operations to Direct Sales Model for Coronary Portfolio
CompanyDeals

OrbusNeich Completes Acquisition of Italian Distributor MC Health – 100% Equity Deal Shifts Italy Operations to Direct Sales Model for Coronary Portfolio

OrbusNeich Medical Group Holdings Limited (HKG: 6929), the medical device company, announced the completion of its acquisition of a 100% equity interest in MC Health S.r.l., an Italian distributor —…

HutchMed Completes USD 1.295 Billion Licensing Transaction with GSK for HMPL‑A830 – First‑in‑Class KRAS‑Inhibitor ATTC Targets EGFR‑Expressing Tumors Globally

HutchMed Completes USD 1.295 Billion Licensing Transaction with GSK for HMPL‑A830 – First‑in‑Class KRAS‑Inhibitor ATTC Targets EGFR‑Expressing Tumors Globally

Biostar's Oral Utidelone Capsule Achieves First Patient Dosing in Phase 3 – Non‑Inferiority Bridging Study vs. Marketed Utidelone Injection in HER2‑Negative Advanced Breast Cancer

Biostar’s Oral Utidelone Capsule Achieves First Patient Dosing in Phase 3 – Non‑Inferiority Bridging Study vs. Marketed Utidelone Injection in HER2‑Negative Advanced Breast Cancer

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Evopoint Biosciences' XNW26018 Wins NMPA Clinical Trial Approval – Novel Class 1 Macrolide Antibiotic Targets Community‑Acquired Bacterial Pneumonia
CompanyDrug

Evopoint Biosciences’ XNW26018 Wins NMPA Clinical Trial Approval – Novel Class 1 Macrolide Antibiotic Targets Community‑Acquired Bacterial Pneumonia